Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib.
Teresa GriecoMartina CavigliaGiuseppina CusanoAlvise SernicolaCamilla ChelloEster Del DucaCarmen CantisaniAlberto TalianoNicolò SiniGianluca IaniroGiovanni PellacaniPublished in: Medicina (Kaunas, Lithuania) (2023)
Background and Objectives : JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis. These drugs target the Janus Kinase intracellular cascade, rendering them suitable for treating both Th1 and Th2 immune-mediated responses. Materials and Methods : We report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1-related disease, and atopic dermatitis, a Th2-mediated condition. Treatment with upadacitinib was initiated, and laboratory and instrumental follow-ups were carried out for 8 months. Results : The complete and persistent clinical remission of both conditions was observed at a low dose of 15 mg of upadacitinib, even though ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse responses to therapy were reported. Conclusions : Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis.